BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20204654)

  • 1. Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
    Kulp J; Levy S; Fein MC; Adams M; Furst J; Meng TC
    Arch Dermatol Res; 2010 Sep; 302(7):539-44. PubMed ID: 20204654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.
    Harrison LI; Skinner SL; Marbury TC; Owens ML; Kurup S; McKane S; Greene RJ
    Arch Dermatol Res; 2004 Jun; 296(1):6-11. PubMed ID: 15083310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
    Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
    Hanke CW; Swanson N; Bruce S; Berman B; Kulp J; Levy S
    J Drugs Dermatol; 2011 Feb; 10(2):165-70. PubMed ID: 21283921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of daily self-application of imiquimod 3.75% cream in adult patients with external anogenital warts.
    Wu J; Feldman R; Barry GT; Kulp J; Adams MP; Levy S
    J Clin Pharmacol; 2012 Jun; 52(6):828-36. PubMed ID: 22232733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
    Quist SR; Gollnick HP
    Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
    Tambone S; Fargnoli MC; Capizzi R; Peris K
    G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
    Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
    J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses.
    Hadley J; Tristani-Firouzi P; Hull C; Florell S; Cotter M; Hadley M
    Dermatol Surg; 2012 May; 38(5):722-7. PubMed ID: 22340282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
    Shaffelburg M
    J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.
    Jorizzo JL; Markowitz O; Lebwohl MG; Bourcier M; Kulp J; Meng TC; Levy S
    J Drugs Dermatol; 2010 Sep; 9(9):1101-8. PubMed ID: 20865842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial.
    Salasche SJ; Levine N; Morrison L
    J Am Acad Dermatol; 2002 Oct; 47(4):571-7. PubMed ID: 12271303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream.
    Stockfleth E; Ulrich C; Lange-Asschenfeldt B; Kremer HJ; Drecoll U; Maus J; Röwert-Huber J
    Eur J Dermatol; 2009; 19(4):355-9. PubMed ID: 19467962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.